Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

BOW-015

Alternative Names: bow-015, bow015, bow 015
Latest Update: 2020-09-10
Latest Update Note: News Article

Product Description

monoclonal antibody against TNF-alpha

Mechanisms of Action: TNF Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Epirus
Company Location: BOSTON MA 02116
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Arthritis, Rheumatoid

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
The UNIFORM Study

P3

Unknown status

Arthritis, Rheumatoid

2017-07-01

Recent News Events

Date

Type

Title

09/10/2020

News Article

 Infliximab Biosimilars Insight Report, 2020 - Comprehensive Insights of 35+ Companies and 45+ Marketed and Pipeline Drugs - ResearchAndMarkets.com

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions